Zetia

Sanofi and Regeneron pay $67.5m to speed alirocumab review

Alirocumab (also known as REGN727) has had positive results in phase III trials, outperforming rival drug Zetia (ezetimibe) from Merck &Co as a monotherapy.

Amgen cholesterol antibody shines in rare disease trial

At the moment, patients are typically treated with a combination of statins, Merck &Co's Zetia (ezetimibe) and other cholesterol-lowering drugs such as niacin, with limited efficacy.

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Alirocumab (also known as REGN727) has shown very positive activity in phase III trials reported to date, outperforming rival drug Zetia (ezetimibe) from Merck &Co as a monotherapy.

Amgen cholesterol antibody scores in another phase III trial

effects. In these people alternative therapies, such as Merck's Zetia (ezetimibe), are used to try to meet treatment goals, and Amgen is banking on evolocumab taking a leadership position among ... And last month the company reported that the antibody

Amgen throws its hat into the cholesterol antibody ring

The reductions seen with the drug were better than those achieved with either placebo or Merck &Co's Zetia (ezetimibe), and consistent with the results seen in phase II trials, said

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]